Chinese Academy of Sciences' R&D of SARS-CoV-2 antibody has entered Phase II clinical trials in the US

Reporter : Sun Zifa / Publisher : China News Network / http://news.sciencenet.cn/htmlnews/2020/10/446551.shtm / Translation, editing : Gan Yung Chyan, KUCINTA SETIA

 

China's progress in the development of SARS-CoV-2 antibodies has attracted much attention. The latest news from the Institute of Microbiology of the Chinese Academy of Sciences said that the JS016 antibody product developed by the institute has started clinical trials in China and the United States in June this year, and the current clinical trials in the United States have entered Phase II.

Specific neutralizing antibodies have both preventive and therapeutic effects, and are known as "biological missiles" aimed at the novel coronavirus. As early as the outbreak of the covid epidemic, the Institute of Microbiology of the Chinese Academy of Sciences began to deploy monoclonal antibody research and development, using a single B-cell antibody screening platform to isolate and screen multiple antibodies from patients in the recovery period, and efficiently cooperate with the company's R&D and industrialization teams. Rapidly conduct multiple parallel development and large-scale production of candidate antibodies.

In June of this year, the monoclonal antibody product JS016 developed by the Institute of Microbiology of the Chinese Academy of Sciences for the prevention and treatment of covid was approved as the world's first clinical trial of a therapeutic antibody for covid in healthy people. The clinical trial was subsequently launched in China and the United States. The trial, and all subjects who completed the Phase I trial in early July were enrolled.

According to the Institute of Microbiology, Chinese Academy of Sciences, the clinical trials of the JS016 antibody product in the United States are advancing at full speed and are now in phase II, which is expected to make important contributions to the prevention and control of the epidemic in China and the world.

Ref:

Antibody (Serology) Testing for COVID-19 : Information for Patients and Consumers, https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers